Get the Stockscreener App
1.96
2.97%
-0.06
After Hours:
2.03
0.07
+3.57%
Alaunos Therapeutics Inc stock is traded at $1.96, with a volume of 9,699.
It is down -2.97% in the last 24 hours and down -7.98% over the past month.
Alaunos Therapeutics Inc is a clinical-stage cellular immuno-oncology company dedicated to the treatment of solid tumors through adoptive TCR-T cell therapy. It strikes cancer at its core by engineering cell therapies that target Neoantigens arising from genomic mutations.
See More
Previous Close:
$2.02
Open:
$2.02
24h Volume:
9,699
Relative Volume:
0.40
Market Cap:
$3.14M
Revenue:
-
Net Income/Loss:
$-36.46M
P/E Ratio:
-12.25
EPS:
-0.16
Net Cash Flow:
$-30.20M
1W Performance:
+3.16%
1M Performance:
-7.98%
6M Performance:
-68.49%
1Y Performance:
-75.11%
1-Day Range:
$1.95
$2.04
1-Week Range:
$1.63
$2.1319
52-Week Range:
$1.63
$32.85
Alaunos Therapeutics Inc Stock (TCRT) Company Profile
Name
Alaunos Therapeutics Inc
Sector
Industry
Phone
(346) 355-4099
Address
2617 BISSONNET ST, HOUSTON
Compare TCRT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TCRT
Alaunos Therapeutics Inc
|
1.96 | 3.14M | 0 | -36.46M | -30.20M | -2.40 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Alaunos Therapeutics Inc Stock (TCRT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-04-22 | Resumed | Wells Fargo | Overweight |
Alaunos Therapeutics Inc Stock (TCRT) Latest News
TCRT stock touches 52-week low at $1.92 amid market challenges - Investing.com
Alaunos Therapeutics Inc (TCRT) Quarterly 10-Q Report - Quartzy
Ziopharm: Q3 Earnings Snapshot - The Washington Post
TCRT Stock Touches 52-Week Low at $1.96 Amid Market Challenges - Investing.com Nigeria
TCRT stock touches 52-week low at $2.06 amid market challenges - Investing.com
Intracranial Therapeutic Market Rewriting its Growth Cycle |Novartis AG, BioMarin, CORESTEM Inc., Alaunos Therapeutics, – IndiaPolitics.com - IndiaPolitics.com
After axing its sole clinical prospect last year, Alaunos cuts ties with Precigen - Fierce Biotech
Alaunos Therapeutics ends key agreement and updates on financial condition By Investing.com - Investing.com Australia
Alaunos Therapeutics Ends Licensing Deal, Reassesses Strategy - Yahoo Finance
Precigen reclaims rights after terminating license agreement - Investing.com India
Precigen Terminates License Agreement With Alaunos Therapeutics - MarketWatch
Alaunos Therapeutics ends key agreement and updates on financial condition - Investing.com
Genentech buys Regor’s CDK inhibitors in $850m deal - Clinical Trials Arena
AskBio and Belief BioMed partner to advance gene therapies - Pharmaceutical Technology
Applied Therapeutics: AdCom Decision Takes Govorestat Approval A Step Closer (NASDAQ:APLT) - Seeking Alpha
An Analysis of Atricure Inc (ATRC)’s Potential Price Growth - Knox Daily
Applied Therapeutics Surges on Positive FDA Update for Govorestat - BP Journal
Applied Therapeutics jumps as US FDA cancels panel meeting for genetic disorder drug - XM
Gene Switch / Molecular Switch Market Set to Reach USD 1.44 Billion by 2031 with 9.9% CAGR - WhaTech
Daily Market Movement: Atricure Inc (ATRC) Sees a -3.23 Decrease, Closing at 27.30 - The Dwinnex
Aptevo Therapeutics announces $3.0M offering priced at-the-market - TipRanks
Check out these key findings about Atricure Inc (ATRC) - SETE News
Atmos Energy Co. (NYSE:ATO) Shares Sold by Prudential PLC - MarketBeat
Gilead and Genesis partner to create novel therapies using AI - Pharmaceutical Technology
Navigator gains $100m in Series A funding for antibody therapeutics - Pharmaceutical Technology
VION Biosciences acquires Echelon Biosciences - Pharmaceutical Technology
TCRT stock touches 52-week low at $2.28 amid market challenges - Investing.com India
Ziopharm: Q2 Earnings Snapshot - San Antonio Express-News
Eli Lilly inaugurates R&D facility in Boston, US - Pharmaceutical Technology
Alaunos Therapeutics (NASDAQ:TCRT) Trading Down 4.2% - Defense World
Genentech and Sangamo to develop neurodegenerative disease therapies - Pharmaceutical Technology
TCRT stock touches 52-week low at $3.57 amid market challenges - Investing.com Nigeria
Alaunos Therapeutics announces 1-for-10 reverse stock split By Investing.com - Investing.com Australia
Alaunos Therapeutics announces 1-for-10 reverse stock split - Investing.com
XyloCor taps SmartWise’s infusion device for gene therapy administration - Clinical Trials Arena
Intracranial Therapeutic Industry Startegy Analysis} Novartis AG, BioMarin, CORESTEM Inc., Alaunos Therapeutics ... - Economica
Alaunos (TCRT) Dips More Than Broader Markets: What You Should Know - Yahoo New Zealand News
Zacks Industry Outlook Highlights Dyne Therapeutics, Silence Therapeutics, Alaunos Therapeutics, Assertio Holdings ... - Yahoo Lifestyle UK
Alaunos Therapeutics appoints new accounting firmInvesting.com ZA - Investing.com South Africa
Alaunos Therapeutics appoints new accounting firm By Investing.com - Investing.com
Ziopharm Oncology to Participate in Upcoming Conferences - Quantisnow
Ziopharm Oncology to Report Fourth Quarter and Full Year 2020 Financial Results and Host Webcast on February 25 ... - Quantisnow
Alaunos Therapeutics Appoints Abhishek Srivastava, Ph.D. as Vice President, Technical Operations - Quantisnow
Turn Bio and HanAll to develop therapies for age-related conditions - Pharmaceutical Technology
AltruBio secures $225m for immune checkpoint programme development - Pharmaceutical Technology
Avenzo Therapeutics secures $150m to bolster oncology pipeline - Pharmaceutical Technology
Gilead concludes acquisition of CymaBay Therapeutics for $4.3bn - Pharmaceutical Technology
Alaunos Therapeutics Inc Stock (TCRT) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):